查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1733192

全球葛瑞夫茲氏病市場規模：按診斷、治療、地區和預測

Global Graves Disease Market Size By Diagnosis (Ultrasound, Imaging Tests, Radioactive Iodine Uptake), By Treatment (Anti- Thyroid Medication, Radioactive Iodine Therapy, Surgery), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

葛瑞夫茲氏病的市場規模與預測

2024年葛瑞夫茲氏病市場規模價值 3.6266億美元，預計到2032年將達到 5.1877億美元，2026年至2032年的年複合成長率為 4.82%。

推動全球葛瑞夫茲氏病市場的因素

葛瑞夫茲氏病市場的市場促進因素可能受到多種因素的影響。這些包括：

  • 格雷夫斯病患病率不斷上升：主要因素之一是格雷夫斯病患病率不斷上升，這是一種導致甲狀腺亢進的自體免疫疾病。隨著確診病例增多，對有效治療方法的需求也隨之增加
  • 改進的治療方法：內分泌學的治療方法和發展為葛瑞夫茲氏病帶來新的、更好的治療方法。藥物治療的創新，包括生技藥品和小分子藥物，改善患者的治療效果和治療反應。
  • 更好的診斷：診斷技術的進步，例如自體抗體檢測和甲狀腺功能檢測，使得葛瑞夫茲氏病的早期和準確診斷成為可能。早期診斷對於有效的管理和治療非常重要。
  • 提升知識和教育程度：大眾和醫學界對葛瑞夫茲氏病的了解越多，診斷越多，治療越及時。病患權益團體和教育宣傳活動是提高人們對病情和可用治療方法的認知的重要工具。
  • 人口老化：隨著世界人口老化，葛瑞夫茲氏病和其他自體免疫疾病變得越來越普遍。自體免疫疾病在老年人中很常見，治療需求日益增加
  • 醫療保健機會的增加：醫療保健服務的改善，特別是在開發中國家，導致葛瑞夫茲氏病的診斷和治療增加。這一趨勢是由政府努力改善醫療基礎設施和醫療改革所推動的。
  • 個人化醫療需求日益增加：個人化醫療越來越受歡迎。這包括根據患者的基因、環境和生活方式特徵做出治療決定。此方法對治療葛瑞夫茲氏病等自體免疫疾病非常有效。
  • 未治療疾病的經濟負擔：未治療或管理不善的格雷夫斯病（包括甲狀腺眼疾和心血管問題等併發症）的經濟負擔是巨大的，需要有效的治療方法來避免這些昂貴的併發症。
  • 為了改善葛瑞夫茲氏病的治療現狀並鼓勵開發新的治療方法，增加公共和私營部門實體以及製藥公司的研發資金將會有所幫助。
  • 技術創新：標靶治療和緩釋性製劑等藥物傳遞方法的發展可以為葛瑞夫茲氏病患者提供更方便、有效的治療選擇。

限制全球葛瑞夫茲氏病市場的因素

有幾個因素可能會對葛瑞夫茲氏病市場造成限制或挑戰。這些包括：

  • 昂貴的治療：藥物治療、放射性碘治療和手術都是葛瑞夫茲氏病昂貴的治療方法的一部分。高昂的費用可能會使患者無法接受這些治療，尤其是在醫療保險和資金匱乏的地區。
  • 葛瑞夫茲氏病的治療方法包括放射性碘、抗甲狀腺藥物和切除術，可能會產生嚴重的副作用和安全問題。這些副作用限制了它們的使用，並可能導致患者停止服藥或不遵守治療計劃。
  • 知識和診斷有限：公眾和一些衛生專業人員通常對格雷夫斯病知之甚少或不甚了解。診斷和治療的延遲會影響患者的治療結果和市場需求。
  • 嚴格的監管標準：治療葛瑞夫茲氏病的新藥必須通過嚴格的監管標準，這使得其生產成本高且耗時。監管障礙可能會延遲新療法的推出並增加相關成本。
  • 競爭性替代療法：放射性碘療法、抗甲狀腺藥物和手術是治療方法的一些有效方法。為了被市場接受，新治療方法必須被證明比現有治療方法更有益，這可能很困難。
  • 治療反應各異：葛瑞夫茲氏病患者對不同治療方法的反應不同，因此很難知道哪種治療方法對每位患者最有效。這種不可預測性會使治療計劃更加困難，並降低治療的整體成功率。
  • 最低限度的研究和開發：與其他慢性疾病相比，葛瑞夫茲氏病患者的數量非常少，因此對新治療方法的研究和開發可能會受到限制。這可能會阻礙治療方法的進步和商業化。
  • 經濟限制：景氣衰退和醫療保健系統預算限制可能會影響葛瑞夫茲氏病昂貴治療方法的接受度。在景氣衰退期間，公共和商業部門對新療法的資金籌措可能會受到限制。
  • 保險和付款問題：對於較新、較昂貴的葛瑞夫茲氏病治療，保險覆蓋範圍和付款有所不同。如果患者必須支付高額的自付費用，他們可能不會尋求最好的照護。
  • 患者依從性：長期使用藥物加上葛瑞夫茲氏病的慢性性質可能會對患者的依從性帶來問題。需要頻繁監測以及可能出現的嚴重副作用可能會影響治療方法的依從性。

目錄

第1章 全球葛瑞夫茲氏病市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章 執行摘要

第3章 已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 全球葛瑞夫茲氏病市場展望

  • 概述
  • 市場動態
    • 促進因素
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章 全球葛瑞夫茲氏病市場（依最終用戶）

  • 概述
  • 醫院
  • 專科診所
  • 門診手術中心
  • 居家醫療

第6章 全球葛瑞夫茲氏病市場（依治療）

  • 概述
  • 抗甲狀腺藥物
  • 放射性碘治療
  • BETA受體阻斷劑
  • 外科治療
  • 輔助性治療
  • 新的治療方法

第7章 全球葛瑞夫茲氏病市場（依通路）

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 專業藥房

第8章 全球葛瑞夫茲氏病市場（依地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東

第8章 全球葛瑞夫茲氏病市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第9章 公司簡介

  • Merck & Co., Inc.
  • Abbott Laboratories
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Allergan, plc
  • RLC LABS
  • Mylan NV
  • AbbVie, Inc.

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 33167

Graves Disease Market Size And Forecast

Graves Disease Market size was valued at USD 362.66 Million in 2024 and is projected to reach USD 518.77 Million by 2032, growing at a CAGR of 4.82% from 2026 to 2032.

Global Graves Disease Market Drivers

The market drivers for the Graves Disease Market can be influenced by various factors. These may include:

  • Growing Prevalence of Graves' Disease: One of the main causes is the rising prevalence of Graves' disease, an autoimmune condition that causes hyperthyroidism. The need for efficient therapies is increasing as more instances are diagnosed.
  • Improvements in Treatment Options: New and better treatments for Graves' disease have been developed as a result of ongoing endocrinology research and development. Drug therapy innovations, such as biologics and small molecule medications, improve patient outcomes and treatment efficacy.
  • Better Diagnostic Methods: The early and more accurate diagnosis of Graves' disease is made possible by technological advancements in diagnostics, such as less intrusive and more accurate tests for autoantibodies and thyroid function. For management and treatment to be effective, early diagnosis is essential.
  • Enhanced Knowledge and Education: A greater public and medical community understanding of Graves' illness results in a greater number of diagnoses and prompt medical management. Patient advocacy groups and educational campaigns are important tools for raising awareness of the symptoms and available treatments.
  • Ageing Population: Graves' disease and other autoimmune disorders are becoming more common as a result of the world's ageing population. Autoimmune disorders are more common in older persons, which increases the need for medical treatments.
  • Increased Access to Healthcare: More cases of Graves' illness are diagnosed and treated as a result of improved access to healthcare services, especially in developing nations. This tendency is facilitated by government initiatives and healthcare reforms that attempt to improve the infrastructure of healthcare.
  • Growing Need for Personalised Medicine: Personalised medicine is becoming more and more popular. It bases treatment decisions on a patient's genetic, environmental, and lifestyle characteristics. This method is very useful for treating autoimmune conditions such as Graves' disease.
  • Economic Burden of Untreated illness: The need for efficient treatments that can avert these expensive complications is driven by the significant economic burden that results from untreated or inadequately managed Graves' illness, including complications like thyroid eye disease and cardiovascular problems.
  • Increased financing for research and development from public and private institutions as well as pharmaceutical corporations helps to improve the current landscape of treatments for Graves' disease and encourage the development of new treatment modalities.
  • Technological Innovations: Patients with Graves' disease benefit from more convenient and effective treatment options thanks to technological developments in drug delivery methods, including as targeted therapy and sustained-release formulations.

Global Graves Disease Market Restraints

Several factors can act as restraints or challenges for the Graves Disease Market. These may include:

  • Expensive Treatment: Medication, radioactive iodine therapy, and surgery are all part of the costly treatment for Graves' illness. Exorbitant expenses may prevent patients from receiving these therapies, particularly in areas with little insurance or financing for healthcare.
  • Treatments for Graves' illness, including radioactive iodine, antithyroid drugs, and thyroidectomy, can have serious adverse effects and raise safety issues. These side effects may restrict their use and cause patients to stop taking their medication or not comply with their treatment plan.
  • Restricted Knowledge and Diagnosis: The general public, as well as some healthcare professionals, frequently have a poor knowledge and comprehension of Graves' illness. Delayed diagnosis and treatment might have an impact on patient outcomes and market demand.
  • Strict Regulatory criteria: New medicines for Graves' disease must pass strict regulatory criteria, which can be expensive and time-consuming to produce. Regulatory obstacles have the potential to postpone the launch of novel treatments and raise their associated expenses.
  • Competition from Alternative Therapies: Radioactive iodine therapy, antithyroid medications, and surgery are some of the proven treatments for Graves' illness. To be accepted by the market, new treatments must shown to be significantly more beneficial than these current options, which might be difficult.
  • Variability in Treatment Response: Individuals with Graves' illness may react differently to various therapies, making it challenging to determine which course of action will work best for each patient. This unpredictability can make treatment plans more difficult to follow and lower the overall success rates of therapy.
  • Minimal Research and Development: Compared to other chronic diseases, Graves' disease patients are very small, hence research and development for novel treatments may be scarce. This may impede the rate of advancement and the launch of novel treatments.
  • Economic Constraints: The adoption of expensive therapies for Graves' disease may be impacted by downturns in the economy and budgetary restrictions in healthcare systems. During recessions, financing for novel treatments from the public and commercial sectors may be constrained.
  • Problems with Insurance and payment: When it comes to newer and more costly therapies, insurance coverage and payment for Graves' disease treatments can be uneven. Significant out-of-pocket expenses for patients may discourage them from obtaining the best care possible.
  • Patient Compliance: Long-term pharmaceutical use combined with the chronic nature of Graves' illness may cause problems with patient compliance. Adherence to treatment methods may be impacted by the necessity for frequent monitoring and the possibility of serious adverse effects.

Global Graves Disease Market: Segmentation Analysis

The Global Graves Disease Market is Segmented on the basis of Treatment Type, End-User, Distribution Channel, and Geography.

Graves Disease Market, By Treatment Type

  • Anti-Thyroid Medications: Drugs used to reduce the production of thyroid hormones. Common medications include methimazole (Tapazole) and propylthiouracil (PTU).
  • Beta-Blockers: Medications that help manage symptoms such as rapid heart rate, tremors, and anxiety. Examples include propranolol and atenolol.
  • Radioactive Iodine Therapy: A treatment that involves ingesting radioactive iodine to destroy overactive thyroid cells, reducing thyroid hormone production.
  • Surgery (Thyroidectomy): A surgical procedure to remove all or part of the thyroid gland, typically used when other treatments are not suitable or effective.
  • Adjunctive Therapies: Supportive treatments including corticosteroids to manage inflammation and immune responses associated with Graves' disease.
  • Emerging Treatments: New therapies under development, including biologics and targeted therapies aimed at the underlying autoimmune aspects of the disease.

Graves Disease Market, By End-User

  • Hospitals: Facilities where comprehensive treatment options including surgery and radioactive iodine therapy are provided.
  • Specialty Clinics: Clinics specializing in endocrinology and thyroid disorders offering specialized care and treatment plans for Graves' disease.
  • Ambulatory Surgical Centers: Outpatient facilities where surgical treatments such as thyroidectomy can be performed.
  • Homecare Settings: For patients managing their condition with medications and regular monitoring at home.

Graves Disease Market, By Distribution Channel

  • Hospital Pharmacies: Pharmacies located within hospitals that dispense medications and provide treatment-related supplies.
  • Retail Pharmacies: Community pharmacies where patients can obtain prescribed medications.
  • Online Pharmacies: E-commerce platforms providing an accessible way for patients to order and receive their medications.
  • Specialty Pharmacies: Pharmacies that focus on complex and chronic conditions, offering personalized services and specialized medications.

Graves Disease Market, By Geography

  • North America: A major market driven by a high prevalence of autoimmune diseases, advanced healthcare infrastructure, and significant R&D activities.
  • Europe: A significant market with growing awareness and diagnosis of thyroid disorders, supported by robust healthcare systems.
  • Asia-Pacific: A rapidly growing market due to increasing healthcare access, rising prevalence of thyroid disorders, and improving healthcare infrastructure.
  • Latin America: An emerging market with increasing healthcare investments and growing awareness about thyroid health.
  • Middle East and Africa: A developing market with improving healthcare facilities and increasing efforts to diagnose and treat thyroid disorders.

Key Players

The "Global Graves Disease Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Merck & Co., Inc., Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline plc, Allergan, plc, RLC LABS, Mylan N.V., AbbVie, Inc., F .Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Jubilant Pharma Holdings Inc., Apitope International NV, Quintiles Inc., Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL GRAVES DISEASE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL GRAVES DISEASE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL GRAVES DISEASE MARKET, BY End-User

  • 5.1 Overview
  • 5.2 Hospitals
  • 5.3 Specialty Clinics
  • 5.4 Ambulatory Surgical Centers
  • 5.5 Homecare Settings

6 GLOBAL GRAVES DISEASE MARKET, BY TREATMENT

  • 6.1 Overview
  • 6.2 Anti-Thyroid Medication
  • 6.3 Radioactive Iodine Therapy
  • 6.4 Beta-Blockers
  • 6.6 Surgery
  • 6.7 Adjunctive Therapies
  • 6.8 Emerging Treatments

7 GLOBAL GRAVES DISEASE MARKET, BY Distribution Channel

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies
  • 7.6 Specialty Pharmacies

8 GLOBAL GRAVES DISEASE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East

8 GLOBAL GRAVES DISEASE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Merck & Co., Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Abbott Laboratories
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Pfizer, Inc.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 GlaxoSmithKline plc
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Allergan, plc
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 RLC LABS
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Mylan N.V.
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AbbVie, Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments

10 Appendix

  • 10.1 Related Research"